[1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.02710.1016/j.ejca.2012.12.02723485231]Open DOISearch in Google Scholar
[2. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990; 250(4988):1684-9. DOI: 10.1126/science.227048210.1126/.2270482]Open DOISearch in Google Scholar
[3. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994; 265(5181):2088-90. DOI: 10.1126/science.809123110.1126/.8091231]Open DOISearch in Google Scholar
[4. Kurian AW, Kingham KE, Ford JM. Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. Curr Opin Obstet Gynecol. 2015; 27(1):23-33. DOI: 10.1097/GCO.000000000000014110.1097/GCO.000000000000014125502425]Open DOISearch in Google Scholar
[5. Hilbers FS, Vreeswijk MP, van Asperen CJ, Devilee P. The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation? Clin Genet. 2013; 84(5):407-14. DOI: 10.1111/cge.1225610.1111/cge.1225624025038]Open DOISearch in Google Scholar
[6. Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014; 145(3):707-14. DOI: 10.1007/s10549-014-2980-010.1007/s10549-014-2980-0417184724807107]Open DOISearch in Google Scholar
[7. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013; 105(11):812-22. DOI: 10.1093/jnci/djt09510.1093/jnci/djt09523628597]Open DOISearch in Google Scholar
[8. Zaky SS, Lund M, May KA, Godette KD, Beitler JJ, Holmes LR, et al. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. Ann Surg Oncol. 2011; 18(10):2858-65. DOI: 10.1245/s10434-011-1669-410.1245/s10434-011-1669-421442346]Search in Google Scholar
[9. Domagala P, Jakubowska A, Jaworska-Bieniek K, Kaczmarek K, Durda K, Kurlapska A, et al. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers. PLoS One. 2015; 10(6):e0130393. DOI: 10.1371/journal.pone.013039310.1371/journal.pone.0130393447115526083025]Search in Google Scholar
[10. Morris JL, Gordon OK. Positive results : making the best decisions when you’re at high risk for breast or ovarian cancer. Amherst, N.Y.: Prometheus Books; 2010. 395 p. p.]Search in Google Scholar
[11. Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016; 14(2):153-62. DOI: 10.6004/jnccn.2016.001810.6004/jnccn.2016.001826850485]Open DOISearch in Google Scholar
[12. Chennagiri N, White EJ, Frieden A, Lopez E, Lieber DS, Nikiforov A, et al. Orthogonal NGS for High Throughput Clinical Diagnostics. Sci Rep. 2016; 6:24650. DOI: 10.1038/srep2465010.1038/srep24650483629927090146]Open DOISearch in Google Scholar
[13. Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000; 67(4):841-50. DOI: 10.1086/30307610.1086/303076128788910978226]Open DOISearch in Google Scholar
[14. Weissgerber TL, Milic NM, Winham SJ, Garovic VD. Beyond bar and line graphs: time for a new data presentation paradigm. PLoS Biol. 2015; 13(4):e1002128. DOI: 10.1371/journal.pbio.100212810.1371/journal.pbio.1002128440656525901488]Search in Google Scholar
[15. Kwong A, Chen JW, Shin VY. A new paradigm of genetic testing for hereditary breast/ovarian cancers. Hong Kong Med J. 2016; 22(2):171-7.10.12809/hkmj15463426980575]Search in Google Scholar
[16. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol. 2007; 25(1):57-63. DOI: 10.1200/JCO.2005.05.516010.1200/JCO.2005.05.516016880452]Open DOISearch in Google Scholar
[17. Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W. Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch. 2011; 458(1):55-64. DOI: 10.1007/s00428-010-0988-310.1007/s00428-010-0988-3301619620941507]Open DOISearch in Google Scholar
[18. Negura L, Uhrhammer N, Negura A, Artenie V, Carasevici E, Bignon YJ. Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population. Fam Cancer. 2010; 9(4):519-23. DOI: 10.1007/s10689-010-9361-610.1007/s10689-010-9361-620567915]Open DOISearch in Google Scholar
[19. Burcos T, Cimponeriu D, Ion DA, Spandole S, Apostol P, Toma M, et al. Analysis of several BRCA1 and BRCA2 mutations in a hospital-based series of unselected breast cancer cases. Chirurgia (Bucur). 2013;108(4):468-72.]Search in Google Scholar
[20. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011; 108(44):18032-7. DOI: 10.1073/pnas.111505210810.1073/pnas.1115052108320765822006311]Open DOISearch in Google Scholar
[21. Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, et al. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer. 2008; 8:140. DOI: 10.1186/1471-2407-8-14010.1186/1471-2407-8-140241325418489799]Search in Google Scholar
[22. Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz- Zaniewska D, Skotnicki P, et al. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hered Cancer Clin Pract. 2016; 14:5. DOI: 10.1186/s13053-016-0046-510.1186/s13053-016-0046-5473908426843898]Open DOISearch in Google Scholar
[23. Cybulski C, Huzarski T, Byrski T, Gronwald J, Debniak T, Jakubowska A, et al. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. Clin Genet. 2009; 75(1):72-8. DOI: 10.1111/j.1399-0004.2008.01111.x10.1111/j.1399-0004.2008.01111.x]Search in Google Scholar
[24. Liu C, Wang Y, Wang QS, Wang YJ. The CHEK2 I157T variant and breast cancer susceptibility: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012; 13(4):1355-60. DOI: 10.7314/APJCP.2012.13.4.135510.7314/APJCP.2012.13.4.1355]Open DOISearch in Google Scholar
[25. Huszno J, Budryk M, Kolosza Z, Tecza K, Pamula Pilat J, Nowara E, et al. A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis. Oncology. 2016; 90(4):193-8. DOI: 10.1159/00044432610.1159/000444326]Search in Google Scholar
[26. Kriege M, Hollestelle A, Jager A, Huijts PE, Berns EM, Sieuwerts AM, et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer. 2014; 111(5):1004-13. DOI: 10.1038/bjc.2014.30610.1038/bjc.2014.306]Open DOISearch in Google Scholar
[27. Cybulski C, Kluzniak W, Huzarski T, Wokolorczyk D, Kashyap A, Jakubowska A, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015; 16(6):638-44. DOI: 10.1016/S1470-2045(15)70142-710.1016/S1470-2045(15)70142-7]Open DOISearch in Google Scholar
[28. Heikkinen T, Karkkainen H, Aaltonen K, Milne RL, Heikkila P, Aittomaki K, et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res. 2009; 15(9):3214-22. DOI: 10.1158/1078-0432.CCR-08-312810.1158/1078-0432.CCR-08-312819383810]Open DOISearch in Google Scholar
[29. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015; 33(4):304-11. DOI: 10.1200/JCO.2014.57.141410.1200/JCO.2014.57.1414430221225452441]Open DOISearch in Google Scholar
[30. Wilson JR, Bateman AC, Hanson H, An Q, Evans G, Rahman N, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.J Med Genet. 2010; 47(11):771-4. DOI: 10.1136/jmg.2010.07811310.1136/jmg.2010.07811320805372]Open DOISearch in Google Scholar
[31. Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol. 2015; 33(21):2345-52. DOI: 10.1200/JCO.2014.59.572810.1200/JCO.2014.59.572826014290]Open DOISearch in Google Scholar
[32. Stagni V, Manni I, Oropallo V, Mottolese M, Di Benedetto A, Piaggio G, et al. ATM kinase sustains HER2 tumorigenicity in breast cancer. Nat Commun. 2015;6:6886. DOI: 10.1038/ncomms788610.1038/ncomms788625881002]Open DOISearch in Google Scholar
[33. Eccles DM, Li N, Handwerker R, Maishman T, Copson ER, Durcan LT, et al. Genetic testing in a cohort of young patients with HER2-amplified breast cancer. Ann Oncol. 2016; 27(3):467-73. DOI: 10.1093/annonc/mdv59210.1093/annonc/mdv59226681682]Open DOISearch in Google Scholar